The main aim was to evaluate the resultant molecular hybrids for potential antiproliferative properties in vitro against a panel of EGFR-positive cancer cell lines2, namely, the human lung cancer (A549), colorectal adenocarcinoma (Caco-2) and the hepatocellular carcinoma (C3A; HepG2/C3A) cell lines as well as the cervical cancer (HeLa) cell line with relatively low EGFR expression.17 This evidence concerns the gene EGFR and colorectal adenocarcinoma.